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NUTRITION & FOOD
SECURITY
§ Presenting the antigen in a multimeric array
increases its immunogenicity.
§ Protection is increased by using nanoparticles to
deliver protective antigens.
§ The technology could be applied for other
antigens/diseases or to generate vaccines to
multiple diseases using the same delivery system.
E.g. TAHSSL bovine respiratory syncytial virus
project.
Nanoparticle platform to fight old 
foes. T. parva p67C antigen as a 
model
Context
• The development of subunit vaccines to East Coast 
fever (ECF) faced the problem to develop a strong 
immune response able to fight the T. parva
sporozoites. 
• The Livestock CRP Group is working in developing 
new delivery systems based on nanoparticles to 
develop a protective immune response to ECF. 
Our innovative approach
• Self-assembled synthetic VLPs increases the 
immune response to a poor model antigen, 
p67C. 
• Self-assembled synthetic VLPs are highly plastic 
and other antigens could be included.
Future steps 
• Continue to apply this technology to continue 
improving the ECF subunit vaccine efficacy. 
• Potential wide use of this technology to develop 
vaccines against other diseases we are working 
under the Livestock CRP, e.g. ECF, ASFV, PPR. 
Outcomes
• Higher immune response to the model antigen, 
p67C. 
• This technology could and will be applied to 
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No limitations on 
antigen size
High plasticity 
